寒冷凝集素症（CAD）- 市場洞察、疫学、市場予測 2028年
Cold Agglutinin Disease (CAD) - Market Insights, Epidemiology, and Market Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||911509|
|出版日||ページ情報||英文 150 Pages
|寒冷凝集素症（CAD）- 市場洞察、疫学、市場予測 2028年 Cold Agglutinin Disease (CAD) - Market Insights, Epidemiology, and Market Forecast - 2028|
|出版日: 2019年09月01日||ページ情報: 英文 150 Pages||
DelveInsight's 'Cold Agglutinin Disease (CAD)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of CAD from 2017 to 2028 segmented by 10 emerging markets.
CAD is an uncommon autoimmune hemolytic anemia (AIHA) in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. CAD is mediated by cold agglutinins (CA), without any obvious underlying disease, such as aggressive lymphoma, other overt malignancies, or specific infections. CA are able to agglutinate red blood cells (RBC) at an optimum temperature of 3-4°C, but are also active at higher temperatures, depending on the thermal amplitude.
Overall, the global Cold Agglutinin Disease therapeutics market has increased over the past few years. The market size is further expected to increase by the major drivers such as rising prevalence and awareness of the disease, current advancements in R&D, promising results of therapies and upcoming therapies in the forecast period [2017-2028].
Study Period: 2017-2028
CAD is a type of AIHA's which consist of warm, cold, or mixed-reactive antibody types that are directed against antigens on the red blood cell (RBC) surface. The autoantibodies may be idiopathic (primary) or related to an underlying condition, such as infection, malignancy, or immune disease (secondary).
Based on the autoantibodies, CAD is classified as primary (unknown cause) or secondary (caused by an underlying condition). Primary Cold Agglutinin Disease is used to describe patients without other systemic autoimmune disease or infective etiology and who have no clinical or radiological evidence of underlying lymphoma. Secondary Cold Agglutinin Disease, is mediated by hemolytic anemia occasionally complicating other specific diseases, such as B cell neoplasias (CLL, Waldenstrom macroglobulinemia, myeloma, other lymphomas), solid tumors (squamous carcinoma of the lung, metastatic adenocarcinoma of the colon, basal cell carcinoma, metastatic adrenal carcinoma, mixed parotid tumor), infections (most frequently Mycoplasma pneumonia, Epstein-Barr virus) or autoimmune diseases (scleroderma, primary Sjogren's syndrome, adult Still's disease, SLE, rheumatoid arthritis). The responsible antibody is monoclonal IgM in B-cell neoplasias and solid tumors and polyclonal IgM in infections, connective tissue diseases, and non-Hodgkin lymphomas.
Emerging markets also does not possess any approved therapy for CAD and relies only on the symptomatic treatment alternatives.
The current therapeutic market of CAD is dominated by non-pharmacological (cold avoidance) and pharmacological management. Corticosteroids, Alkylating agents, Purine nucleoside analogs and majorly Biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab) and others are the major therapeutic line of treatment for CAD.
The CAD epidemiology division provides insights about historical and current patient pool and forecasted trends of 10EM countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent cases, Gender-Specific Prevalence, Age-Specific Prevalence and Type-Specific Prevalent cases of CAD ) scenario of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan. 2017-2028.
According to DelveInsight, the total prevalent cases of CAD in the 10EM was found to be 29,077 in 2017. The prevalence of CAD in the 10EM is expected to increase during the study period of 2017-2028.
This segment of the CAD report encloses the detailed analysis of emerging drugs and other promising drugs. It also helps to understand the clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Pharmacological management of Cold Agglutinin disease included corticosteroids, alkylating agents, purine nucleoside analogs and biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab), in some cases, Bortezomib alone or in combination can also be used. These are used as the mainstay of treatment in emerging markets.
Rituximab monotherapy is recommended as the first-line treatment and several case reports indicate that Rituximab is an effective drug in some cases of CAD. Since Rituximab has been in use, the reduction in the numbers of cold antibodies has caused a significant improvement in hemoglobin levels. Patients who relapse after having responded to Rituximab may receive another course of Rituximab or proceed to the combination therapy, depending on an individualized assessment.
Detailed chapters of emerging therapies such as Sutimlimab (BIVV009) (Sanofi), APL-2 (Pegcetacoplan) (Apellis Pharmaceuticals) and promising Bortezomib (Janssen Pharmaceutical), Parsaclisib (Incyte Corporation), and others have also been provided in the report.
The CAD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
According to DelveInsight, the market for CAD in 10EM was found to be approximately USD 26.80 Million in 2017.
China accounted for 33% of the total market of CAD in 2017. Due to the high prevalence of this disease in the region, the CAD treatment market in China is expected to dominate the market during the forecast period (2019-2028).
This section focusses on the emerging drugs present in the market and promising drugs in the market or the drugs that are expected to get launched in the market during the study period from 2017-2028. The analysis covers patient uptake by therapies and sales of each drug.
The launch of Complement pathway inhibitors such as Sutimlimab (Sanofi), APL-2 (Apellis Pharmaceuticals) is anticipated to revolutionize the overall market scenario.